ISSN: 1307-5888 | E-ISSN: 2757-7392 | Contact
The effect of transarterial chemoembolization therapy on survival in patients with non-resectable hepatocellular carcinoma: Single-center study results
1Dicle University, Faculty of Medicine, Department of Radiology, Şanlıurfa, Tur
2Harran University, Faculty of Medicine, Department of Radiology, Şanlıurfa, Turkey
3Kanuni Sultan Süleyman Training and Research Hospital, İstanbul, Turkey
Hepatology Forum 2021; 3(2): 102-106 DOI: : 10.14744/hf.2021.2021.0029 PMCID: PMC9138947
Full Text PDF


Background and Aims: This study aimed to investigate the tumor response and effect of treatment on survival in patients diagnosed with hepatocellular carcinoma (HCC) undergoing drug-eluting transarterial chemoembolization (DEB-TACE).
Material and Methods: 40 patients who underwent DEB-TACE between March 2018 and November 2020 were retrospectively analyzed. The patients were followed up with abdominal computed tomography, serum albumin, bilirubin, prothrombin time, and α-fetoprotein values. European Association for Study of the Liver criteria were used to evaluate the treatment response.
Results: A total of 70 TACE sessions were performed in 40 patients with HCC. The etiology of the patients was chronic hepatitis B vırus (n=32), secondary biliary cirrhosis (n=2), cryptogenic (n=2), chronic hepatitis C vırus (n=4). Based on TACE response, complete response was observed in 22 patients, partial response in 8 patients, and progression in 10 patients. Liver transplantation was performed in 4 patients who developed complete response. In addition, the formation of new nodules was observed in 8 patients during the follow-up period, whereas 29 patients survived and 11 died.
Conclusion: In this study, it was found that DEB-TACE had a positive effect on the survival of patients diagnosed with HCC who could not be surgically treated.